Gregory D Cuny

Houston, TX, United States of America

Gregory D Cuny

USPTO Granted Patents = 69 

 

 

Average Co-Inventor Count = 5.1

ph-index = 16

Forward Citations = 665(Granted Patents)

Forward Citations (Not Self Cited) = 617(Oct 12, 2025)


Location History:

  • Woodbury, MN (US) (1997 - 2003)
  • Hudson, MA (US) (2000 - 2006)
  • Somerville, MA (US) (2004 - 2015)
  • Cambridge, MA (US) (2015)
  • Houston, TX (US) (2013 - 2024)

Company Filing History:

goldMedal31 out of 1,370 
 
The Brigham and Women's Hospital, Inc.
 patents
silverMedal24 out of 322 
 
Sepracor, Inc.
 patents
bronzeMedal8 out of 2,961 
 
Harvard College
 patents
45 out of 262 
 
Massachusetts Eye and Ear Infirmary
 patents
55 out of 588 
 
University of Houston System
 patents
64 out of 7,865 
 
Minnesota Mining and Manufacturing Company
 patents
74 out of 172 
 
Tufts University
 patents
84 out of 2,882 
 
The General Hospital Corporation
 patents
93 out of 259 
 
Brandeis University
 patents
103 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
113 out of 1,206 
 
Dana-farber-cancer Institute Inc.
 patents
123 out of 459 
 
Tufts College
 patents
132 out of 621 
 
Imation Corporation
 patents
142 out of 818 
 
Boston University
 patents
152 out of 14,059 
 
3m Innovative Properties Company
 patents
162 out of 842 
 
University of Georgia Research Foundation, Inc.
 patents
172 out of 2 
 
Yuma Therapeutics, Inc.
 patents
181 out of 827 
 
The Ohio State University
 patents
191 out of 2,007 
 
Duke University
 patents
201 out of 3,086 
 
Chinese Academy of Sciences
 patents
211 out of 2 
 
Aquinnah Pharmaceuticals, Inc.
 patents
221 out of 769 
 
Indiana University
 patents
where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...
Loading Chart...
Loading Chart...
69 patents (USPTO):

Title: Innovations by Gregory D. Cuny in Pharmaceutical Chemistry

Introduction

Gregory D. Cuny, a prolific inventor based in Somerville, MA, is known for his significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 38 patents, Cuny’s work primarily focuses on developing innovative compounds aimed at treating various health disorders, particularly those related to obesity and necroptosis.

Latest Patents

Among Gregory D. Cuny's latest patents are groundbreaking inventions involving phosphatidylcholine transfer protein inhibitors and heterocyclic inhibitors of necroptosis. The first invention discusses compounds represented by Formulas I, II, and III, which serve as inhibitors of phosphatidylcholine transfer protein (PC-TP). This work addresses pharmaceutical compositions and therapeutic methods targeting disorders associated with obesity through the inhibition of PC-TP.

The second patent highlights a series of heterocyclic derivatives designed to inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. These compounds, detailed in Formulas (I) and (Ia)-(Ie), have been shown to inhibit necroptosis in FADD-deficient human Jurkat T cells. This innovative approach could pave the way for new treatments where necroptosis plays a significant role, showcasing Cuny's dedication to advancing medical science.

Career Highlights

Gregory D. Cuny has worked with prominent organizations, including Sepracor, Inc. and Brigham and Women's Hospital. His tenure at these institutions has provided him with valuable experience and insight into the pharmaceutical industry, which has undoubtedly influenced his prolific inventorship.

Collaborations

Throughout his career, Gregory D. Cuny has collaborated with talented professionals, including James R. Hauske and Brian M. Aquila. These partnerships have fostered innovative research and development efforts, leading to the successful creation of numerous impactful patents in the field.

Conclusion

Gregory D. Cuny’s innovative work and extensive patent portfolio demonstrate his significant impact on pharmaceutical advancements. His inventions hold promise for developing treatments to combat obesity and related disorders, along with other health issues where necroptosis is a critical factor. Cuny’s dedication to research and collaboration continues to inspire future innovations in the field of pharmaceutical chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…